Advisory Services Network’s VistaGen Therapeutics VTGN Stock Holding History

Advisory Services Network’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3	Closed	–	–	3192
2021 Q2	$0	Buy	+3	New	+$222	﹤0.01%	3651

Other funds holding VTGN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Advisory Services Network's VTGN Position: Q3 2021 in Review

Advisory Services Network sold out of VistaGen Therapeutics (VTGN) in Q3 2021, closing a stake of 3 shares.

Advisory Services Network first reported a position in VTGN in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 104 funds tracked by Wall St. Rank hold VTGN as of Q3 2021.

Advisory Services Network reported no remaining VistaGen Therapeutics position as of Q3 2021 after selling out during the quarter.
Advisory Services Network sold 3 VistaGen Therapeutics shares in Q3 2021.
Advisory Services Network first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 1 quarter.
Advisory Services Network's VistaGen Therapeutics position peaked at $0 in Q2 2021.
104 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2021.

Based on Advisory Services Network's 13F filing for Q3 2021, filed 5 Nov 2021.